This article is more than 5 years old. Information may no longer be current.

Misonix announces entry into surgical wound debridement

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Misonix Inc. has announced its immediate entry into surgical wound debridement by adding their SonicOne technology to the BoneScalpel surgical platform. The BoneScalpel with SonicOne Technology is designed for surgical wound debridement and is an updated and expanded version of the existing BoneScalpel product.

“Misonix is excited about entering a new segment of the large and growing wound care market, particularly a segment characterized by significant use of high tech disposables,” Michael A. McManus, Jr., president and chief executive officer of Misonix, stated in the company press release.

Misonix’s strategy is to market a range of products to effect a complete wound healing protocol for surgery, according to the release. The BoneScalpel with SonicOne Technology is a companion product to the recently announced Hyalomatrix skin substitute and will be positioned accordingly.